Melanocortin receptor agonist
PT-141
Bremelanotide
FDA-approved for a narrow indicationBremelanotide is an FDA-approved prescription medicine under the brand Vyleesi for a specific form of hypoactive sexual desire disorder in premenopausal women.
FULL RESEARCH GRAPHIC
PT-141 research overview
A dedicated overview of bremelanotide, melanocortin-receptor signaling, and the 10 mg vial.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
FDA-approved for a narrow indicationIts approved indication is not a general endorsement for libido enhancement, men, postmenopausal women, or sexual performance.
BOUNDARY CHECK
CONTEXT REQUIREDThe FDA label includes limitations of use and safety warnings. Unapproved products should not be treated as interchangeable with the approved drug-device product.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
10 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
3.0 mL BAC-water workflow
- First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
- Clean both vial stoppers with alcohol and allow them to dry.
- Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
- Gently roll or swirl until dissolved; do not shake.
- Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
Vyleesi label: 1.75 mg as needed
The approved prefilled autoinjector delivers 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours or eight doses per month. The indication is acquired, generalized HSDD in premenopausal women.
FDA prescribing information — Vyleesi ↗U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.